Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026)
Soleno Therapeutics' (SLNO) quarterly Income from Continuing Operations came in at 31378000.0 in Q1 2026, up 171.68% year-on-year from 11549470.2 in Q1 2025, and down 27.85% on a QoQ basis from 43489000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Income from Continuing Operations data on file, last reported at 31378000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 171.68% year-over-year to 31378000.0 in Q1 2026; TTM through Mar 2026 was 185209000.0, a 49.29% increase from a year earlier, with the FY2025 full-year figure at 53539000.0, up 79.34% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 31378000.0, down from 43489000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for SLNO reached as high as 43489000.0 in Q4 2025 and fell as low as 173917000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 48212325.41 across 5 years, with a median of 43773000.0 in 2025.
- Across the five-year window, Income from Continuing Operations slumped 1080.64% in 2024 and soared 178.03% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 62627000.0 in 2022, then surged by 81.63% to 11502000.0 in 2023, then tumbled by 384.56% to 55734000.0 in 2024, then surged by 178.03% to 43489000.0 in 2025, then fell by 27.85% to 31378000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 31378000.0 in Q1 2026, 43489000.0 in Q4 2025, and 86159000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.49 Mn |
| Sep 30, 2025 | -86.16 Mn |
| Jun 30, 2025 | -173.92 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.73 Mn |
| Sep 30, 2024 | -173.76 Mn |
| Jun 30, 2024 | -91.99 Mn |
| Mar 31, 2024 | -100.06 Mn |
| Dec 31, 2023 | -11.50 Mn |
| Sep 30, 2023 | -58.17 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -62.63 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -7.13 Mn |
| Mar 31, 2022 | -6.22 Mn |
| Dec 31, 2021 | -54.32 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -11.70 Mn |